Table 1 Performance of Combined method in the diagnosis of HCC
From: The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis
Test cohort (151HCC + 145LC) | Validation cohort (112HCC + 88LC) | |||||||
|---|---|---|---|---|---|---|---|---|
N | Sensitivity (95% CI) | Specificity (95% CI) | Accuracy (95% CI) | N | Sensitivity (95% CI) | Specificity (95% CI) | Accuracy (95% CI) | |
Combined method | ||||||||
BCLC 0-C | 151 | 89.40 (83.09–93.63) | 80.69 (73.13–86.58) | 85.14 (81.08–89.19) | 112 | 81.25 (72.54–87.77) | 81.82 (71.85–88.94) | 81.5 (76.12–86.88) |
BCLC 0 + A | 36 | 80.56 (63.43–91.20) | 80.69 (73.13–86.58) | 80.66 (74.91–86.42) | 27 | 66.67 (46.02–82.76) | 81.82 (71.85–88.94) | 78.26 (70.72–85.80) |
BCLC 0 | 5 | 60 (17.04–92.74) | 80.69 (73.13–86.58) | 80 (73.60–86.40) | 7 | 42.86 (11.81–79.76) | 81.82 (71.85–88.94) | 78.95 (70.75–87.15) |
BCLC A | 31 | 83.87 (65.53–93.90) | 80.69 (73.13–86.58) | 81.25 (75.48–87.02) | 20 | 75.00 (50.59–90.41) | 81.82 (71.85–88.94) | 80.56 (73.09–88.02) |
BCLC B | 36 | 88.89 (73.00–96.38) | 80.69 (73.13–86.58) | 82.32 (76.76–87.88) | 28 | 82.14 (62.42–93.23) | 81.82 (71.85–88.94) | 81.90 (74.89–88.90) |
BCLC C | 79 | 93.67 (85.21–97.65) | 80.69 (73.13–86.58) | 85.27 (80.63–89.91) | 57 | 87.72 (75.71–94.51) | 81.82 (71.85–88.94) | 84.14 (78.19–90.08) |
AFP (cutoff value: 400ng/mL) | ||||||||
BCLC 0-C | 151 | 28.48 (21.58–36.49) | 98.62 (94.60–99.76) | 62.84 (57.33–68.34) | 112 | 23.21 (15.98–32.32) | 98.86 (92.95–99.94) | 56.5 (49.63–63.37) |
BCLC 0 + A | 36 | 19.44 (8.80–36.57) | 98.62 (94.60–99.76) | 82.87 (77.38–88.36) | 27 | 7.41 (1.29–25.75) | 98.86 (92.95–99.94) | 77.39 (69.75–85.04) |
BCLC 0 | 5 | 20.00 (1.05–70.12) | 98.62 (94.60–99.76) | 96 (92.86–99.14) | 7 | 0.00 (0.00–0.00) | 98.86 (92.95–99.94) | 91.58 (85.99–97.16) |
BCLC A | 31 | 19.35 (8.12–38.06) | 98.62 (94.60–99.76) | 84.66 (79.33–89.98) | 20 | 10 (1.75–33.13) | 98.86 (92.95–99.94) | 82.41 (75.23–89.59) |
BCLC B | 36 | 27.78 (14.79–45.43) | 98.62 (94.60–99.76) | 84.53 (79.26–89.80) | 28 | 25 (11.43–45.22) | 98.86 (92.95–99.94) | 81.03 (73.90–88.17) |
BCLC C | 79 | 32.91 (23.00–44.50) | 98.62 (94.60–99.76) | 75.45 (69.81–81.08) | 57 | 29.82 (18.80–43.57) | 98.86 (92.95–99.94) | 71.72 (64.39–79.05) |
AFP (cutoff value: 20ng/mL) | ||||||||
BCLC 0-C | 151 | 56.29 (47.99–64.27) | 91.03 (84.85–94.95) | 73.31 (68.27–78.35) | 112 | 48.21 (38.75–57.81) | 93.18 (85.19–97.20) | 68 (61.54–74.46) |
BCLC 0 + A | 36 | 47.22 (30.76–64.27) | 91.03 (84.85–94.95) | 82.32 (76.76–87.88) | 27 | 22.22 (9.38–42.73) | 93.18 (85.19–97.20) | 76.52 (68.77–84.27) |
BCLC 0 | 5 | 40 (7.26–82.96) | 91.03 (84.85–94.95) | 89.33 (84.39–94.27) | 7 | 14.29 (0.75–57.99) | 93.18 (85.19–97.20) | 87.37 (80.69–94.05) |
BCLC A | 31 | 48.39 (30.56–66.60) | 91.03 (84.85–94.95) | 83.52 (78.04–89.00) | 20 | 25.00 (9.60–49.41) | 93.18 (85.19–97.20) | 80.56 (73.09–88.02) |
BCLC B | 36 | 50.00 (33.22–66.78) | 91.03 (84.85–94.95) | 82.87 (77.38–88.36) | 28 | 39.29 (22.13–59.27) | 93.18 (85.19–97.20) | 80.17 (72.92–87.43) |
BCLC C | 79 | 63.29 (51.64–73.64) | 91.03 (84.85–94.95) | 81.25 (76.14–86.36) | 57 | 64.91 (51.06–76.76) | 93.18 (85.19–97.20) | 82.07 (75.83–88.31) |